The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Eisai; Eisai; Janssen; Janssen
Research Funding - Eisai; Eisai

A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.
 
Hilary Glen
No Relationships to Disclose
 
Javier Puente
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche
Research Funding - Astellas Oncology; Pfizer
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst)
 
Sun Young Rha
Honoraria - Eisai
 
Di Li
Employment - Eisai
 
Daniel E. Stepan
Employment - Eisai
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation